Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

Reviewing common effects of hormonal therapy in patients with breast cancer.

Reviewing common effects of hormonal therapy in patients with breast cancer.

Posted by on May 23, 2021 in Breast cancer | 0 comments

In a nutshell This article reviewed the common side effects of estrogen deprivation during hormonal therapy for women with breast cancer and provided an update on alternative therapies to manage these symptoms. Some background Breast cancer (BC) is one of the most common cancers affecting women worldwide. Some BC cells grow in response to female...

Read More

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Posted by on May 16, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the real-world safety and effectiveness of the palbociclib (Ibrance) plus letrozole (Femara) versus letrozole alone in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC). The data concluded that palbociclib in combination with...

Read More

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Which is safer for the heart: tamoxifen or letrozole?

Which is safer for the heart: tamoxifen or letrozole?

Posted by on Nov 30, 2020 in Breast cancer | 0 comments

In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...

Read More

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More

How effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?

Posted by on Aug 14, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations.  Some background Breast cancer (BC) types can be...

Read More

EndoPredict – can this prognostic test predict treatment success in breast cancer?

Posted by on May 30, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC.  Some background Breast cancer (BC) is one of the most common cancers. BC treatment...

Read More